RNAi-based technologies have the potential to enhance many aspects of the anti-cancer drug development process. The increased use of anti-cancer therapeutics targeting specific genetic characteristics (e.g., a fusion transcript or over-expression/amplification of a gene) illustrates the impact molecular analysis has had on the development of anti-tumor agents. Further, there is growing awareness that the genetic background of an individual can influence a patients response to anti-cancer therapeutics. Studies focused on assessing the contribution of genetic and transcriptional variation to a drug response phenotype have become more sophisticated as larger data sets integrating drug-activity with genome-wide DNA/RNA analysis are reported. However, functional approaches to understanding the relationships predicted by these studies have been lacking. We are using RNAi analysis and screening to probe the impact of gene-specific expression on drug-activity, including identification of new proteins that directly or indirectly modulate the pharmacology of anti-cancer therapeutics. We have used the power of RNAi analysis to investigate gene-drug interactions, including study of multi-drug resistance and the activity of the anti-leukemia agent L-Asparaginase. We have also initiated screens that combine RNAi with drug administration. The identification of molecular targets that can act to modulate the activity of anti-cancer drugs has become an important application for RNAi screening approaches. This approach combines RNAi with administration of a small molecule compound or biologic to identify proteins whose down-regulation modulates the activity of a therapeutic agent. This approach has the potential to enhance the clinical application of an established or investigational drug by: (1) identifying synergistic molecular targets that exploit complementary vulnerabilities within a cancer cell, (2) enabling the use of lower concentrations of a drug that exhibits dose-dependent non-specific toxicities, (3) overcoming drug resistance, and, (4) broadening the clinical application of a drug to other cancer types. We began our drug-RNAi screening projects focusing on a chemosensitization (synthetic-lethal) approach using a clinical relevant drug with a defined molecular target and mode of action, the topoisomerase 1 inhibitor camptothecin (CPT), to enable validation of our screens in the context of established drug activity. In FY10 we published a study that highlighted the role of the ribonucleotide reductase subunit RRM2 in the cellular response to CPT. The expression of RRM2 is significantly up-regulated in cells following addition of CPT. Silencing of RRM2 gene expression through RNAi and other proteins required for this response act to enhance the cytotoxicity of CPT. We have also expanded on analysis of the anti-leukemia agent L-Asparaginase to include multi-dose drug treatment with RNAi and have identified a possible mechanism underlying a relationship between asparaginase synthetase (ASNS) and L-Asparaginase. Planned RNAi screens will begin to examine drugs with less defined or more complex mechanism of action and/or drugs undergoing pre-clinical or early clinical testing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010939-03
Application #
8157537
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2010
Total Cost
$475,663
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Maachani, Uday Bhanu; Kramp, Tamalee; Hanson, Ryan et al. (2015) Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins. Mol Cancer Res 13:852-62
Garimella, Sireesha V; Gehlhaus, Kristie; Dine, Jennifer L et al. (2014) Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening. Breast Cancer Res 16:R41
Tandle, Anita T; Kramp, Tamalee; Kil, Whoon J et al. (2013) Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation. Eur J Cancer 49:3020-8
Bennett, Christina N; Tomlinson, Christine C; Michalowski, Aleksandra M et al. (2012) Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. Breast Cancer Res 14:R109
Martin, S E; Wu, Z-H; Gehlhaus, K et al. (2011) RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors. Curr Cancer Drug Targets 11:976-86
Murrow, Lyndsay M; Garimella, Sireesha V; Jones, Tamara L et al. (2010) Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 122:347-57
Zhang, Yong-Wei; Jones, Tamara L; Martin, Scott E et al. (2009) Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. J Biol Chem 284:18085-95
Jobson, Andrew G; Lountos, George T; Lorenzi, Philip L et al. (2009) Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther 331:816-26
Calcagno, A M; Fostel, J M; To, K K W et al. (2008) Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer 98:1515-24